Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05984615 · ClinicalTrials.gov registry record
Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients
A clinical trial of BRAF Positive Metastatic Melanoma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,961
- Enrollment target
- 1
- Study location
NCT05984615 is a study of BRAF Positive Metastatic Melanoma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,961 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05984615, a study of BRAF Positive Metastatic Melanoma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,961 participants
- Enrollment target
- 1
- Study location
Study Summary
This was a retrospective real-world evidence cohort study.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,961 participants |
| Start Date | 2022-06-08 |
| Est. Completion | 2022-08-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05984615
The ClinicalTrials.gov registry entry for NCT05984615 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,961 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with BRAF Positive Metastatic Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT05984615 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05984615 about?
NCT05984615 is a clinical study titled "Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients". This was a retrospective real-world evidence cohort study.
What is the current status of trial NCT05984615?
This trial is currently completed. The enrollment target is 1,961 participants. The study started on 2022-06-08. Estimated completion is 2022-08-24.
What conditions does trial NCT05984615 study?
This clinical trial studies the following conditions: BRAF Positive Metastatic Melanoma.
Who is sponsoring clinical trial NCT05984615?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05984615 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.